浩欧博(688656) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥109,620,064.63, representing a year-over-year increase of 6.09%[5] - Net profit attributable to shareholders decreased by 15.16% to ¥17,062,565.35 for the same period[5] - Total operating revenue for the first three quarters of 2023 reached ¥300,153,994.57, a 17.9% increase from ¥254,601,087.79 in the same period of 2022[23] - Operating profit for the first three quarters of 2023 was ¥43,360,389.54, down 14.5% from ¥50,539,210.18 in the previous year[24] - Net profit for the first three quarters of 2023 was ¥38,633,884.75, a decrease of 13.5% compared to ¥44,471,980.35 in the same period of 2022[24] - Total comprehensive income for the first three quarters of 2023 was ¥38,633,884.75, a decrease of 13.5% from ¥44,471,980.35 in the same period of 2022[25] Cash Flow - The cash flow from operating activities increased significantly by 91.89% to ¥30,846,241.22[6] - Cash flow from operating activities for the first three quarters of 2023 was ¥71,594,957.40, an increase of 64.3% from ¥43,582,718.50 in the previous year[27] - The company reported a net cash flow from operating activities of ¥330,298,955.00 for the first three quarters of 2023, compared to ¥280,948,136.97 in the previous year, reflecting a positive trend in cash generation[27] - The net cash flow from financing activities was -$25,069,502.07, compared to -$21,514,391.60 in the previous period, indicating a decline in financing cash flow[28] - Total cash and cash equivalents at the end of the period reached $187,510,918.21, up from $94,043,154.72 in the previous period, showing a significant increase[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥953,833,802.19, reflecting a slight increase of 0.98% from the previous year[6] - The company's current assets decreased to RMB 384,116,634.94 from RMB 422,983,685.22 at the end of 2022, representing a decline of approximately 9.2%[17] - Total liabilities decreased to RMB 152,345,653.21 from RMB 164,986,872.55, reflecting a reduction of about 7.7%[20] - The company's equity attributable to shareholders increased to RMB 801,488,148.98 from RMB 779,571,748.70, marking an increase of approximately 2.2%[20] Shareholder Information - The company reported a total of 3,654 common shareholders at the end of the reporting period[12] - The largest shareholder, Hai Rui Xiang Tian Biotechnology Group Co., Ltd., holds 55.66% of the shares[12] Research and Development - Research and development expenses totaled ¥12,792,723.26, accounting for 11.67% of revenue, an increase of 1.84 percentage points year-over-year[6] - The company experienced a 38.14% increase in R&D investment year-to-date, driven by ongoing project investments and increased personnel costs[9] Earnings Per Share - The basic earnings per share for Q3 2023 was ¥0.27, down 15.63% compared to the same period last year[6] - Basic earnings per share for the third quarter of 2023 was ¥0.61, down from ¥0.71 in the same quarter of 2022[25] - Diluted earnings per share for the third quarter of 2023 was ¥0.60, compared to ¥0.70 in the previous year[25] Inventory and Accounts - Inventory rose significantly to RMB 115,191,681.41, up from RMB 87,801,859.39, indicating a growth of approximately 31.1%[19] - The accounts payable decreased significantly to RMB 21,023,833.08 from RMB 48,330,147.79, a reduction of approximately 56.5%[19] - The company reported a total of RMB 42,144,676.74 in accounts receivable, up from RMB 32,377,969.41, representing an increase of about 30%[17] Cash Management - Cash inflow from investment activities for the first three quarters of 2023 was ¥455,946,250.88, down 18.0% from ¥555,460,176.85 in the same period of 2022[27] - Cash outflow from investment activities for the first three quarters of 2023 was ¥468,365,250.36, a decrease of 49.8% compared to ¥933,196,211.92 in the previous year[27] - The company paid $35,129,541.67 for debt repayment, which is an increase from $20,000,000.00 in the previous period[28] - Dividend payments and interest totaled $19,815,470.71, down from $34,356,677.75 in the previous period, reflecting a reduction in shareholder returns[28] Other Financial Metrics - The weighted average return on equity decreased to 2.15%, down 0.45 percentage points year-over-year[6] - The beginning cash and cash equivalents balance was $153,303,587.42, compared to $449,855,143.38 in the previous period, indicating a decrease in available cash at the start of the period[28] - The company did not apply new accounting standards or interpretations for the current year[28]